SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Medical Oncology (gastrointestinal) Consultation — Lorraine Hansberry — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientLorraine Hansberry
Date of birth1930-05-19
IdentifiersMRN HR-ML034-SYN-TD; SSN (made up) 000-34-7158
Document date1963-05-04
AuthorSamuel Adeyemi-Rourke, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

Suspected pancreatic or duodenal cancer in a 32-year-old playwright with two months of epigastric pain boring through to the back, a 5 kg weight loss, black stools with iron deficiency anemia (hemoglobin 9.1 g/dL, ferritin 6 ng/mL), new diabetes (A1c 6.6%) and a cholestatic liver pattern. Upper endoscopy and pancreas-protocol CT are booked this week. Please see her within two weeks to review the results with her and plan treatment if cancer is found. [S]

Urgency: Urgent, within two weeks. [S]

Questions for the consultant:

History of Present Illness

Ms. Hansberry, 32, is seen at the request of Dr. Marchetti-Fields two weeks after she presented with two months of epigastric and back pain, weight loss, black stools with iron deficiency anemia, and new diabetes. Since then she has had an upper endoscopy, a pancreas-protocol CT, an endoscopic ultrasound with biopsy and a biliary stent, two doses of intravenous iron, and review at our pancreatic tumor board. The pain is 6 out of 10 and breaks her sleep; her stools are pale and float after fatty meals; there has been no black stool since the iron. She works at home as a playwright and is active most of the day (ECOG 1). She is not pregnant and has no children. She asked for the facts in plain words. [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

5 later historical claims are omitted because they describe events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfastOne tablet daily before breakfastOral route1963-04-20activeS
Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart750 mg intravenously; two doses one week apartIntravenous route1963-04-24 to 1963-05-01completedS
Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for painOne tablet every 4 hours as neededOral route1963-05-04activeS
Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodoneTwo tablets at nightOral route1963-05-04activeS
Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snackTwo capsules with each meal, one with each snackOral route1963-05-04 to 1963-10-05completedS

Problems

ProblemClinical statusVerificationCodeProvenance
Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this weekresolvedconfirmed R10.13S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mLactiveconfirmed D50.0S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers.
New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2resolvedconfirmed R73.09S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit.
Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differentlyactiveconfirmed C25.0S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md.
Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dLactiveconfirmed E08.9S — Synthetic consequence of the synthetic tumor.
Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight lossactiveconfirmed K86.81S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer.
Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by itactiveconfirmed G89.3S — Synthetic symptom of the synthetic tumor.
Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCPactiveconfirmed K83.1S — Synthetic consequence of the synthetic tumor.

Physical Exam

Vital signs recorded on 1963-05-04; see the referring visit's Vital Signs section. [S]

SystemFinding
GeneralThin, tired, composed; weight 55.4 kg; blood pressure 108/68, pulse 92; ECOG 1
EyesSlight scleral icterus, less than at the first visit
AbdomenEpigastric tenderness without guarding; no mass, liver enlargement or ascites
Lymph nodesNo supraclavicular nodes; no umbilical nodule

Results

DateMeasureValueUnitReference rangeFlagProvenance
1963-05-04Hemoglobin [Mass/volume] in Blood10.4g/dL12-15.5 g/dLLowS
1963-05-04Leukocytes [#/volume] in Blood by Automated count710*3/uL4-11 10*3/uLNormalS
1963-05-04Neutrophils [#/volume] in Blood by Automated count4.610*3/uL1.5-7.7 10*3/uLNormalS
1963-05-04Platelets [#/volume] in Blood by Automated count36610*3/uL150-400 10*3/uLNormalS
1963-05-04Creatinine [Mass/volume] in Serum or Plasma0.68mg/dL0.59-1.04 mg/dLNormalS
1963-05-04Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1958)/1.73 sq M119mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1963-05-04Glucose [Mass/volume] in Serum or Plasma141mg/dL70-99 mg/dLHighS
1963-05-04Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-35 U/LNormalS
1963-05-04Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L8-35 U/LNormalS
1963-05-04Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma168U/L35-104 U/LHighS
1963-05-04Bilirubin.total [Mass/volume] in Serum or Plasma0.9mg/dL0.1-1.2 mg/dLNormalS
1963-05-04Albumin [Mass/volume] in Serum or Plasma3.5g/dL3.5-5 g/dLNormalS
1963-05-04Cancer Ag 19-9 [Units/volume] in Serum or Plasma486U/mL<=35 U/mLHighS
1963-05-04Carcinoembryonic Ag [Mass/volume] in Serum or Plasma3.9ng/mLUp to 3.0 ng/mL in non-smokersHighS
1963-05-04INR in Platelet poor plasma by Coagulation assay1{INR}0.8-1.2NormalS
1963-05-04Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1963-05-04Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S
1963-05-04Pain severity - 0-10 verbal numeric rating [Score] - Reported6{score}S

Assessment

Data reviewed: Dr. Marchetti-Fields's intake note and results. Upper endoscopy: an ulcerated, oozing mass on the medial wall of the second part of the duodenum beside the papilla, no peptic ulcer; biopsies: adenocarcinoma infiltrating from the pancreas. Pancreas-protocol CT with CT of the chest: 3.1 cm hypoattenuating mass in the pancreatic head invading the duodenum; common bile duct 13 mm and pancreatic duct 5 mm; contact with about 200 degrees of the superior mesenteric vein with short-segment narrowing that can be reconstructed; no contact with the superior mesenteric artery, celiac axis or common hepatic artery; no liver, peritoneal or lung lesion. EUS-guided biopsy: pancreatic adenocarcinoma, moderately differentiated; extra cores held for molecular profiling. ERCP: fully covered metal stent across a distal bile duct stricture. Today: bilirubin 0.9 mg/dL, alkaline phosphatase 168 U/L, CA 19-9 486 U/mL (after drainage), CEA 3.9 ng/mL, hemoglobin 10.4 g/dL, neutrophils 4.6, platelets 366, creatinine 0.68 mg/dL, albumin 3.5 g/dL, fasting glucose 141 mg/dL, INR 1.0. [S]

Plan of Treatment